PULM Pulmatrix Corporation: Enterprise Value to EBITDA Ratio
The visualized share price of Pulmatrix, Inc. (PULM) with an EV/EBITDA ratio of 0.00 is based on the engagement of external contractors for drug manufacturing and research. Pulmatrix, Inc. (PULM) is developing the iSPERSE closed B2B environment, integrating its proprietary systems into the products of industry behemoths. Revenue stability is ensured by the perpetual need of patients for inhalation therapy, which creates a long-term profit stream from the use of proprietary formulas.
Comprehensive metric breakdowns and analytics for pulmatrix.com (PULM)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
- financial results and valuation multiples details:
PULM - Net Income|Projected Future Earnings Pulmatrix, Inc.|PULM - P/E Multiple|Projected Price to Earnings Pulmatrix, Inc.|PULM - Company Value to Earnings Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pulmatrix Corporation|PULM - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Pulmatrix|PULM - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months pulmatrix.com|PULM - Earnings per share growth this year|Expected earnings per share growth for next year Pulmatrix, Inc.
Fundamental valuation:Pulmatrix Corp (PULM)
The development of the unique iSPERSE drug delivery system creates significant licensing value for Pulmatrix, Inc. (PULM), which directly impacts the business valuation. By analyzing the historical EV/EBITDA trajectory, an investor can observe the ratio of the company's enterprise value to its operating profit, enabling an assessment of the real asset value and the effectiveness of debt load management over time.
Competitors of Pulmatrix, Inc.
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANI Pharmaceuticals, Inc. ANIP|MNKD (MannKind Corp) - Company Value to Operating Income Before Depreciation Ratio|AMPH: Enterprise Value to EBITDA Ratio|PCRX - EV/EBITDA Multiple|ARS Pharmaceuticals (SPRY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TBPH (theravance.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aquestive Therapeutics, Inc.|Enterprise Value to EBITDA Ratio scPharma (SCPH)|EV/EBITDA Multiple TECX|EV/EBITDA Multiple Tonix Pharmaceuticals Holding (TNXP)|China SXT Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio EPRX (Eupraxia Pharmaceuticals, Inc.)|BHST - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation EXOZ (Invizyne Technologies)|ORMP: EV/EBITDA Multiple|ENTX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio HYFT|Enterprise Value to Operating Income Before Depreciation ABVC (abvcpharma.com)|Enterprise Value to EBITDA Ratio CPIX (Cumberland Pharmaceuticals Inc.)|QNTM (Quantum BioPharma Ltd.) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple FGEN (FibroGen Corp)|Total Company Value to Operating Income Before Depreciation Ratio Telomir Pharmaceuticals Corp (TELO)|RANI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SNYR (Synergy CHC Corp) - Enterprise Value to Operating Income Before Depreciation|RLYB: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Lexaria Bioscience Corp.|Enterprise Value to EBITDA Ratio PTHL|Aptorum (APM) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lyra Therapeutics, Inc. (LYRA)|IBO: Company Value to Operating Income Before Depreciation Ratio|TNF Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple cbdMD Inc. YCBD|PRFX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CYTO: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Lipella Pharmaceuticals (LIPO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio optinose.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharmaceuticals, Inc.|Procaps Group - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PTPI|QLI (Qilian International Corp) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SLRN (Acelyrin, Inc.)|EV/EBITDA Multiple tffpharma.com TFFP
